The role of the AR/ER ratio in ER-positive breast cancer patients

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer

(2017) Yuka Asano et al.   Cancers

Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis

(2016) Mohammad A. Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up

(2016) Sara Bustreo et al.   BREAST CANCER RESEARCH AND TREATMENT

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

(2016) Erik Hilborn et al.   BRITISH JOURNAL OF CANCER

Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms

(2016) J Feng et al.   ONCOGENE

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Androgen receptor status is highly conserved during tumor progression of breast cancer

(2015) André Grogg et al.   BMC CANCER

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer

(2015) Andrew Ciupek et al.   BREAST CANCER RESEARCH AND TREATMENT

Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis

(2015) Yoonseok Kim et al.   Journal of Breast Cancer

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

(2014) Yassine Rechoum et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma

(2014) Rika Fujii et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations

(2014) Mirco Pistelli et al.   Cancers

A simple and reproducible prognostic index in luminal ER-positive breast cancers

(2013) I. Castellano et al.   ANNALS OF ONCOLOGY

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

(2013) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

(2013) F. E. Vera-Badillo et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Research Resource: Interplay between the Genomic and Transcriptional Networks of Androgen Receptor and Estrogen Receptor α in Luminal Breast Cancer Cells

(2012) Eleanor F. Need et al.   MOLECULAR ENDOCRINOLOGY

Expression and clinical significance of androgen receptor in triple negative breast cancer

(2012) Xiang Luo et al.   Chinese Journal of Cancer

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers

(2011) S. Park et al.   ANNALS OF ONCOLOGY

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

(2011) R. Hu et al.   CLINICAL CANCER RESEARCH

Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy

(2011) Ashley Cimino-Mathews et al.   HUMAN PATHOLOGY

Expression of androgen receptor in breast cancer and its significance as a prognostic factor

(2010) Q. Yu et al.   ANNALS OF ONCOLOGY

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

(2010) Isabella Castellano et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

(2010) E Mrozek et al.   CANCER RESEARCH

Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment

(2010) Kiyoshi Takagi et al.   ENDOCRINE-RELATED CANCER

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of androgen receptors in primary breast cancer

(2009) S. Park et al.   ANNALS OF ONCOLOGY

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

(2009) Leo A Niemeier et al.   MODERN PATHOLOGY

Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

(2008) Luis O Gonzalez et al.   BMC CANCER

Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors

(2008) Elisa J. Cops et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-α-positive and -negative breast cancer cells

(2008) Hung-Yun Lin et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY